prnewswire.com · 22 jun

Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA).

zacks.com · 15 jun

LH vs. CRL: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com · 8 jun

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com · 5 jun

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

seekingalpha.com · 3 jun

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

zacks.com · 1 jun

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.

gurufocus.com · 29 may

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer PR Newswire BURLINGTON,

prnewswire.com · 29 may

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).